在美国人群中检验对脂肪性肝病命名变更的临时提案
基于美国人群调查数据,采用振动控制瞬时弹性成像评估脂肪肝,将人群分为非酒精性脂肪性肝病、酒精相关脂肪性肝病和病毒性肝炎脂肪性肝病。共纳入5102人,三类患病率分别为25.43%、6.95%和0.73%,病毒性肝炎脂肪性肝病组临床显著纤维化比值比显著高于非酒精性脂肪性肝病组。
要点
- 美国人群中非酒精性脂肪性肝病、酒精相关脂肪性肝病和病毒性肝炎脂肪性肝病加权患病率分别为25.43%、6.95%和0.73%。
- 病毒性肝炎脂肪性肝病组临床显著纤维化比值比显著高于非酒精性脂肪性肝病组(OR 3.76,95%CI 1.27-11.14,p=0.02)。
- 三组间进展期纤维化和肝硬化的比值比无显著差异。
核心结论
- 当前分析评估了共识会议讨论提出的命名变更,脂肪性肝病命名尊重 underlying liver etiology 并减少污名化,同时提高对病毒性和酒精相关脂肪性/脂肪性肝炎的认识。
研究设计与样本
- 使用美国人群数据集进行调查加权分析的横断面研究,共纳入5102人,采用振动控制瞬时弹性成像评估脂肪肝。
主要发现
- 调查加权分析显示,25.43%被分类为非酒精性脂肪性肝病,6.95%为酒精相关脂肪性肝病,0.73%为病毒性肝炎脂肪性肝病。
- 在受控衰减参数248 dB/m和脂肪肝指数进行的敏感性分析中发现了相似的分布。
- 非酒精性脂肪性肝病、酒精相关脂肪性肝病和病毒性肝炎脂肪性肝病三组间进展期纤维化和肝硬化的比值比无显著差异。
- 病毒性肝炎脂肪性肝病组临床显著纤维化比值比显著高于非酒精性脂肪性肝病组(OR 3.76,95%CI 1.27-11.14,p=0.02)。
关键数值与推荐
- 受控衰减参数288 dB/m用于识别肝脂肪变。
- 肝脏硬度≥8.8 kPa、≥11.7 kPa和≥14 kPa分别用于识别临床显著纤维化、进展期纤维化和肝硬化。
- 敏感性分析使用受控衰减参数248 dB/m和脂肪肝指数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Fatty liver is the commonest liver condition globally and traditionally associated with NAFLD. A consensus meeting was held in Chicago to explore various terminologies. Herein, we explore the proposed changes in nomenclature in a population data set from the US. APPROACH AND RESULTS: Statistical analysis was conducted using survey-weighted analysis. Assessment of fatty liver was conducted with vibration-controlled transient elastography. A controlled attenuation parameter of 288 dB/m was used to identify hepatic steatosis. Patients were classified into nonalcoholic steatotic liver disease, alcohol-associated steatotic liver disease, and viral hepatitis steatotic liver disease. Liver stiffness measures at ≥8.8, ≥11.7, and ≥14 kPa were used to identify clinically significant fibrosis, advanced fibrosis, and cirrhosis, respectively. A total of 5102 individuals were included in the analysis. Using a survey-weighted analysis, a total of 25.43%, 6.95%, and 0.73% of the population were classified as nonalcoholic steatotic liver disease, alcohol-associated steatotic liver disease, and viral hepatitis steatotic liver disease, respectively. A sensitivity analysis at controlled attenuation parameter of 248 dB/m and fatty liver index found similar distribution. In a comparison between nonalcoholic steatotic liver disease, alcohol-associated steatotic liver disease, and viral hepatitis steatotic liver disease, there was no significant difference between the odds of advanced fibrosis and cirrhosis between groups. However, viral hepatitis steatotic liver disease individuals were found to have a significantly higher odds of clinically significant fibrosis (OR: 3.76, 95% CI, 1.27-11.14, p =0.02) compared with nonalcoholic steatotic liver disease. CONCLUSIONS: The current analysis assessed the proposed changes based on discussions from the consensus meeting. Although the definitions are an interim analysis of discussions, steatotic liver disease respects the underlying liver etiology and reduces stigma while increasing awareness of FL among viral and alcohol-associated steatosis/steatohepatitis.
引用
- Ng CH, Chan KE, Muthiah M, et al. Examining the interim proposal for name change to steatotic liver disease in the US population. Hepatology. 2023. PMID: 36645228. doi:10.1097/HEP.0000000000000043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。